Journal of Bone Oncology

Papers
(The TQCC of Journal of Bone Oncology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Bone metastases in thyroid cancer51
Separation surgery for metastatic epidural spinal cord compression: A qualitative review39
Prognostic factors in osteosarcoma: A study level meta-analysis and systematic review of current practice37
Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis36
New perspective into mesenchymal stem cells: Molecular mechanisms regulating osteosarcoma36
Exosomes derived from bone marrow mesenchymal stem cells promote osteosarcoma development by activating oncogenic autophagy35
Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review33
Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer27
Targeting ferroptosis in osteosarcoma24
Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group24
Baicalin induces apoptosis and autophagy in human osteosarcoma cells by increasing ROS to inhibit PI3K/Akt/mTOR, ERK1/2 and β-catenin signaling pathways22
Potential diagnostic value of miRNAs in peripheral blood for osteosarcoma: A meta-analysis22
Malignancy in giant cell tumor of bone in the extremities21
Current strategies for the treatment of solitary and aneurysmal bone cysts: A review of the literature21
Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval20
The HMGB1/RAGE axis induces bone pain associated with colonization of 4T1 mouse breast cancer in bone20
The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer20
Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma18
Neurological outcomes after surgery for spinal metastases in symptomatic patients: Does the type of decompression play a role? A comparison between different strategies in a 10-year experience17
Luteolin attenuates the chemoresistance of osteosarcoma through inhibiting the PTN/β-catenin/MDR1 signaling axis by upregulating miR-38417
Role of microRNAs in the crosstalk between osteosarcoma cells and the tumour microenvironment16
LncRNA SNHG16 promotes epithelial-mesenchymal transition by upregulating ITGA6 through miR-488 inhibition in osteosarcoma16
Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal co16
Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review16
ceRNA network development and tumour-infiltrating immune cell analysis of metastatic breast cancer to bone16
Sensory nerves: A driver of the vicious cycle in bone metastasis?15
Adapting palliative radiation therapy for bone metastases during the Covid-19 pandemic: GEMO position paper15
The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties14
Osteoporosis management in hematologic stem cell transplant recipients: Executive summary14
The inhibition of MARK2 suppresses cisplatin resistance of osteosarcoma stem cells by regulating DNA damage and repair14
Prediction of the early recurrence in spinal giant cell tumor of bone using radiomics of preoperative CT: Long-term outcome of 62 consecutive patients14
Periacetabular reconstruction following limb-salvage surgery for pelvic sarcomas13
Giant cell tumor of bone: A single center study of 115 cases12
MiR-451a promotes cell growth, migration and EMT in osteosarcoma by regulating YTHDC1-mediated m6A methylation to activate the AKT/mTOR signaling pathway12
In vitro three-dimensional cell cultures for bone sarcomas12
Clonality analysis and IDH1 and IDH2 mutation detection in both components of dedifferentiated chondrosarcoma, implicated its monoclonal origin11
Potential diagnostic value of circulating miRNA for multiple myeloma: A meta-analysis11
One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma11
Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer11
Surgical outcomes of metastatic bone tumors in the extremities (Surgical outcomes of bone metastases)10
Clarifying prognostic factors of small cell osteosarcoma: A pooled analysis of 20 cases and the literature10
Primary bone lymphoma: Clinical presentation and therapeutic considerations10
ELF1-activated FOXD3-AS1 promotes the migration, invasion and EMT of osteosarcoma cells via sponging miR-296-5p to upregulate ZCCHC310
All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma10
Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of WHO fracture risk assessment tool (FRAX) and bone mineral density in real-life clinical pr10
Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey10
Development and validation of a cuproptosis-related lncRNA model correlated to the cancer-associated fibroblasts enable the prediction prognosis of patients with osteosarcoma10
c-Met expression in renal cell carcinoma with bone metastases10
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)9
von Willebrand factor promotes platelet-induced metastasis of osteosarcoma through activation of the VWF-GPIb axis9
Primary perivascular epithelioid cell tumor (PEComa) in bone: A review of the literature and a case arising in the humerus with multiple metastases9
Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations9
Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?9
Heterogeneity of chondrosarcomas response to irradiations with X-rays and carbon ions: A comparative study on five cell lines9
Identifying biomolecules and constructing a prognostic risk prediction model for recurrence in osteosarcoma9
Clinical course of grafted cartilage in osteoarticular frozen autografts for reconstruction after resection of malignant bone and soft-tissue tumor involving an epiphysis9
Chondroblastoma: Is intralesional curettage with the use of adjuvants a sufficient way of therapy?9
Delay in diagnosis of primary osteosarcoma of bone in children: Have we improved in the last 15 years and what is the impact of delay on diagnosis?9
Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial9
Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices9
Epidemiology and detection of cement leakage in patients with spine metastases treated with percutaneous vertebroplasty: A 10-year observational study9
0.025525093078613